1. Home
  2. MLYS vs REAX Comparison

MLYS vs REAX Comparison

Compare MLYS & REAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • REAX
  • Stock Information
  • Founded
  • MLYS 2019
  • REAX 2018
  • Country
  • MLYS United States
  • REAX United States
  • Employees
  • MLYS N/A
  • REAX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • REAX
  • Sector
  • MLYS Health Care
  • REAX
  • Exchange
  • MLYS Nasdaq
  • REAX Nasdaq
  • Market Cap
  • MLYS 1.0B
  • REAX 849.5M
  • IPO Year
  • MLYS 2023
  • REAX N/A
  • Fundamental
  • Price
  • MLYS $13.67
  • REAX $3.88
  • Analyst Decision
  • MLYS Strong Buy
  • REAX Strong Buy
  • Analyst Count
  • MLYS 4
  • REAX 3
  • Target Price
  • MLYS $27.00
  • REAX $6.33
  • AVG Volume (30 Days)
  • MLYS 692.8K
  • REAX 855.7K
  • Earning Date
  • MLYS 08-12-2025
  • REAX 08-07-2025
  • Dividend Yield
  • MLYS N/A
  • REAX N/A
  • EPS Growth
  • MLYS N/A
  • REAX N/A
  • EPS
  • MLYS N/A
  • REAX N/A
  • Revenue
  • MLYS N/A
  • REAX $1,417,877,000.00
  • Revenue This Year
  • MLYS N/A
  • REAX $44.55
  • Revenue Next Year
  • MLYS N/A
  • REAX $16.68
  • P/E Ratio
  • MLYS N/A
  • REAX N/A
  • Revenue Growth
  • MLYS N/A
  • REAX 81.30
  • 52 Week Low
  • MLYS $8.24
  • REAX $3.80
  • 52 Week High
  • MLYS $18.38
  • REAX $6.75
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 45.18
  • REAX 39.26
  • Support Level
  • MLYS $13.41
  • REAX $3.81
  • Resistance Level
  • MLYS $15.15
  • REAX $4.17
  • Average True Range (ATR)
  • MLYS 0.73
  • REAX 0.15
  • MACD
  • MLYS 0.01
  • REAX -0.02
  • Stochastic Oscillator
  • MLYS 25.36
  • REAX 11.67

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

Share on Social Networks: